Announced details
Annual production capacity for small-molecule pharmaceuticals will increase from approximately 2.0 billion tablets to approximately 3.6 billion tablets.
Maximum annual production capacity for highly potent pharmaceutical products of approximately 400 million tablets
Storage capacity for approximately 160 pallets of sterile formulations at 2–8°C
Alfresa Pharma Corporation is our subsidiary. It manufactures pharmaceuticals and related products.
3038-2 Serada-cho, Ota, Gunma Prefecture
The impact on results for the current fiscal year is expected to be minor. Over the medium to long term, we believe the facility will contribute to enhancing corporate value.
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Small-molecule pharmaceuticals, Contract manufacturing of highly potent pharmaceutical products, Contract testing, inspection and packaging of sterile formulations |
| Relationship with the Company | Alfresa Pharma Corporation is our subsidiary. It manufactures pharmaceuticals and related products. |
| Launch date | 1 April 2026 (the new manufacturing building’s operating date; commercial production is targeted to begin after process qualification (PQ) and process validation (PV)) |
| Applicable area | Prescription Pharmaceuticals, OTC formulations, Anticancer drugs, Hormonal formulations |
| Location | 3038-2 Serada-cho, Ota, Gunma Prefecture |
| Location scale | Three stories above ground, 23.4 m high, with a total floor area of approximately 11,680 m² (approximately 3,533 tsubo) |
| Quantitative Effects | Annual production capacity for small-molecule pharmaceuticals will increase from approximately 2.0 billion tablets to approximately 3.6 billion tablets., Maximum annual production capacity for highly potent pharmaceutical products of approximately 400 million tablets, Storage capacity for approximately 160 pallets of sterile formulations at 2–8°C |
| Impact on Business Performance | The impact on results for the current fiscal year is expected to be minor. Over the medium to long term, we believe the facility will contribute to enhancing corporate value. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To expand contract manufacturing and establish a more efficient, high-quality manufacturing system. The new building will strengthen the production system for small-molecule pharmaceuticals and enable full-scale entry into contract manufacturing of highly potent pharmaceutical products, as well as contract testing, inspection and packaging of sterile formulations.